Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
23 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
GHU APHP NUP SITE BICHAT C BERNARD
46 R HENRI HUCHARD, 75877 PARIS CEDEX 18
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
PURPOSEAlthough NRG1 fusions are oncogenic drivers across multiple tumor types including lung cancers, these are difficult to study because of their rarity. The global eNRGy1 registry was thus established to characterize NRG1 fusion–positive lung cancers in the largest and most diverse series to date.METHODSFrom June 2018 to February 2020, a consortium of 22 centers from nine countries in Europe, Asia, and the United States contributed data from patients with pathologically confirmed NRG1 fusion–positive lung cancers. Profiling included DNA-based and/or RNA-based next-generation sequencing and fluorescence in situ hybridization. Anonymized clinical, pathologic, molecular, and response (RECIST v1.1) data were centrally curated and analyzed.RESULTSAlthough the typified never smoking (57%), mucinous adenocarcinoma (57%), and nonmetastatic (71%) phenotype predominated in 110 patients with NRG1 fusion–positive lung cancer, further diversity, including in smoking history (43%) and histology (43% nonmucinous and 6% nonadenocarcinoma), was elucidated. RNA-based testing identified most fusions (74%). Molecularly, six (of 18) novel 5′ partners, 20 unique epidermal growth factor domain–inclusive chimeric events, and heterogeneous 5′/3′ breakpoints were found. Platinum-doublet and taxane-based (post–platinum-doublet) chemotherapy achieved low objective response rates (ORRs 13% and 14%, respectively) and modest progression-free survival medians (PFS 5.8 and 4.0 months, respectively). Consistent with a low programmed death ligand-1 expressing (28%) and low tumor mutational burden (median: 0.9 mutations/megabase) immunophenotype, the activity of chemoimmunotherapy and single-agent immunotherapy was poor (ORR 0%/PFS 3.3 months and ORR 20%/PFS 3.6 months, respectively). Afatinib achieved an ORR of 25%, not contingent on fusion type, and a 2.8-month median PFS.CONCLUSIONNRG1 fusion–positive lung cancers were molecularly, pathologically, and clinically more heterogeneous than previously recognized. The activity of cytotoxic, immune, and targeted therapies was disappointing. Further research examining NRG1-rearranged tumor biology is needed to develop new therapeutic strategies.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2022
The oncologist · 2021
AbstractBackgroundNeuregulin 1 (NRG1) fusions, which activate ErbB signaling, are rare oncogenic drivers in multiple tumor types. Afatinib is a pan-ErbB family inhibitor that may be an effective treatment for NRG1 fusion-driven tumors.Patients and MethodsThis report summarizes pertinent details, including best tumor response to treatment, for six patients with metastatic NRG1 fusion-positive tumors treated with afatinib.ResultsThe six cases include four female and two male patients who ranged in age from 34 to 69 years. Five of the cases are patients with lung cancer, including two patients with invasive mucinous adenocarcinoma and three patients with nonmucinous adenocarcinoma. The sixth case is a patient with colorectal cancer. NRG1 fusion partners for the patients with lung cancer were either CD74 or SDC4. The patient with colorectal cancer harbored a novel POMK-NRG1 fusion and a KRAS mutation. Two patients received afatinib as first- or second-line therapy, three patients received the drug as third- to fifth-line therapy, and one patient received afatinib as fifteenth-line therapy. Best response with afatinib was stable disease in two patients (duration up to 16 months when combined with local therapies) and partial response (PR) of >18 months in three patients, including one with ongoing PR after 27 months. The remaining patient had a PR of 5 months with afatinib 40 mg/day, then another 6 months after an increase to 50 mg/day.ConclusionThis report reviews previously published metastatic NRG1 fusion-positive tumors treated with afatinib and summarizes six previously unpublished cases. The latter include several with a prolonged response to treatment (>18 months), as well as the first report of efficacy in NRG1 fusion-positive colorectal cancer. This adds to the growing body of evidence suggesting that afatinib can be effective in patients with NRG1 fusion-positive tumors.Key PointsNRG1 fusions activate ErbB signaling and have been identified as oncogenic drivers in multiple solid tumor types. Afatinib is a pan-ErbB family inhibitor authorized for the treatment of advanced non-small cell lung cancer that may be effective in NRG1 fusion-driven tumors. This report summarizes six previously unpublished cases of NRG1 fusion-driven cancers treated with afatinib, including five with metastatic lung cancer and one with metastatic colorectal cancer. Several patients showed a prolonged response of >18 months with afatinib treatment. This case series adds to the evidence suggesting a potential role for afatinib in this area of unmet medical need.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
JTO clinical and research reports · 2025 · Journal Article
Gounant V, Greillier L, Mascaux C, Pinquie F, et al.
Translational oncology · 2025 · Journal Article
Levallet G, Creveuil C, Léger-Vigot A, Brosseau S, et al.
Respiratory medicine and research · 2025 · Journal Article
Bouchez C, Medraoui C, Cazes A, Khalil A, et al.
BMC pulmonary medicine · 2024 · Journal Article
Brudon A, Fournier D, Selle F, Seront E, et al.
Lung cancer (Amsterdam, Netherlands) · 2023 · Clinical Trial, Phase III
Levallet G, Dubois F, Elie N, Creveuil C, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2023 · Letter
Moghadam P, Herms F, Baroudjian B, Tetu P, et al.
International journal of cancer · 2022 · Clinical Trial, Phase III
Maille E, Levallet J, Dubois F, Antoine M, et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2022 · Journal Article
Gounant V, Ferré VM, Soussi G, Charpentier C, et al.
Therapeutic advances in medical oncology · 2021 · Journal Article
Gounant V, Brosseau S, Zalcman G
Lung cancer (Amsterdam, Netherlands) · 2021 · Journal Article
Vauchier C, Pluvy J, Theou-Anton N, Soussi G, et al.
ERJ open research · 2021 · Journal Article
Guenzi E, Pluvy J, Guyard A, Nguenang M, et al.
Journal of clinical medicine · 2020 · Journal Article
Herbreteau G, Langlais A, Greillier L, Audigier-Valette C, et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2019 · Case Reports
Abbar B, Henry C, Theou-Anton N, Brosseau S, et al.
Cancers · 2022 · Journal Article
Aregui A, Pluvy J, Sanchez M, Israel T, et al.
Lung cancer (Amsterdam, Netherlands) · 2020 · Journal Article
Gounant V, Lavolé A, Quoix E
Respiratory medicine and research · 2026 · Journal Article
Lajoinie P, Fallet V, Wislez M, du Rusquec P, et al.
Rheumatology (Oxford, England) · 2021 · Journal Article
Weill A, Delyon J, Descamps V, Deschamps L, et al.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2025 · Journal Article
Dall'Olio FG, Zrafi W, Roelants V, Ambrosini V, et al.
The oncologist · 2021 · Journal Article
Cadranel J, Liu SV, Duruisseaux M, Branden E, et al.
European journal of cancer (Oxford, England : 1990) · 2024 · Journal Article
Ebstein E, Brocard P, Soussi G, Khoury R, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021 · Journal Article
Drilon A, Duruisseaux M, Han JY, Ito M, et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026 · Journal Article
Zalcman G, Madroszyk A, Guenzi E, Dayen C, et al.
JTO clinical and research reports · 2025 · Journal Article
Lucibello F, Gounant V, Aldea M, Duruisseaux M, et al.